KR20160130248A - 손발톱 및 두피 건선의 치료 방법 - Google Patents

손발톱 및 두피 건선의 치료 방법 Download PDF

Info

Publication number
KR20160130248A
KR20160130248A KR1020167026333A KR20167026333A KR20160130248A KR 20160130248 A KR20160130248 A KR 20160130248A KR 1020167026333 A KR1020167026333 A KR 1020167026333A KR 20167026333 A KR20167026333 A KR 20167026333A KR 20160130248 A KR20160130248 A KR 20160130248A
Authority
KR
South Korea
Prior art keywords
antibody
psoriasis
seq
composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167026333A
Other languages
English (en)
Korean (ko)
Inventor
아자이 니룰라
히데미 나카가와
켄지 오다키
히로키 마츠도
폴 클렐코트카
그레고리 크리코리안
Original Assignee
키린-암젠, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키린-암젠, 인코포레이티드 filed Critical 키린-암젠, 인코포레이티드
Priority to KR1020227021274A priority Critical patent/KR102530900B1/ko
Publication of KR20160130248A publication Critical patent/KR20160130248A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y10S514/863—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
KR1020167026333A 2014-03-31 2015-03-19 손발톱 및 두피 건선의 치료 방법 Ceased KR20160130248A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227021274A KR102530900B1 (ko) 2014-03-31 2015-03-19 손발톱 및 두피 건선의 치료 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461972638P 2014-03-31 2014-03-31
US61/972,638 2014-03-31
US201462031850P 2014-07-31 2014-07-31
US62/031,850 2014-07-31
US201462041879P 2014-08-26 2014-08-26
US62/041,879 2014-08-26
PCT/US2015/021613 WO2015153144A1 (en) 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021274A Division KR102530900B1 (ko) 2014-03-31 2015-03-19 손발톱 및 두피 건선의 치료 방법

Publications (1)

Publication Number Publication Date
KR20160130248A true KR20160130248A (ko) 2016-11-10

Family

ID=52808190

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167026333A Ceased KR20160130248A (ko) 2014-03-31 2015-03-19 손발톱 및 두피 건선의 치료 방법
KR1020227021274A Active KR102530900B1 (ko) 2014-03-31 2015-03-19 손발톱 및 두피 건선의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227021274A Active KR102530900B1 (ko) 2014-03-31 2015-03-19 손발톱 및 두피 건선의 치료 방법

Country Status (11)

Country Link
US (1) US20170174772A1 (https=)
EP (1) EP3126392B1 (https=)
JP (1) JP6596014B2 (https=)
KR (2) KR20160130248A (https=)
CN (1) CN106456751B (https=)
AU (1) AU2015241373B2 (https=)
CA (1) CA2944605C (https=)
ES (1) ES2760002T3 (https=)
MY (1) MY184189A (https=)
SG (1) SG11201607881SA (https=)
WO (1) WO2015153144A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
JP7033774B2 (ja) * 2017-08-25 2022-03-11 国立大学法人 東京大学 抗サイトカイン抗体療法
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
WO2019163945A1 (ja) 2018-02-22 2019-08-29 学校法人東海大学 Ｉｌ－１７ａ活性阻害剤およびその用途
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2021048359A1 (en) * 2019-09-11 2021-03-18 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
KR20220070244A (ko) * 2019-09-25 2022-05-30 도꾜 다이가꾸 전신성 강피증 치료용 의약 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ES2072330T5 (es) 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
CA2032191C (en) 1989-12-13 1999-05-18 David Wallach Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US7030565B2 (en) 2004-07-27 2006-04-18 Jerrell Penn Hollaway Lamp control circuit with selectable color signals
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
HRP20171939T1 (hr) * 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
PH12013500660B1 (en) * 2010-10-08 2017-10-27 Novartis Ag Methods of treating psoriasis using il-17 antagonists
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CN106456751B (zh) 2021-02-02
CA2944605A1 (en) 2015-10-08
MY184189A (en) 2021-03-24
CN106456751A (zh) 2017-02-22
EP3126392A1 (en) 2017-02-08
ES2760002T3 (es) 2020-05-12
JP6596014B2 (ja) 2019-10-23
JP2017511316A (ja) 2017-04-20
KR102530900B1 (ko) 2023-05-12
US20170174772A1 (en) 2017-06-22
AU2015241373A1 (en) 2016-10-06
AU2015241373B2 (en) 2020-11-05
SG11201607881SA (en) 2016-10-28
WO2015153144A1 (en) 2015-10-08
KR20220093008A (ko) 2022-07-04
CA2944605C (en) 2023-10-17
EP3126392B1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
AU2015241373B2 (en) Methods of treating nail and scalp psoriasis
US12383572B2 (en) Administration of an anti-activin-a compound to a subject
RU2707745C2 (ru) Способы лечения или профилактики мигренозной головной боли
RU2563830C2 (ru) Лечение остеоартрита и боли
CA2969341C (en) Anti-csf1r antibodies for treating pvns
KR20220047826A (ko) 고 농도의 항-c5 제형
CN114630842A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2017512193A (ja) Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
KR20210086671A (ko) 항-vegf 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
AU2016330471A1 (en) Antibodies that bind human cannabinoid 1 (CB1) receptor
JP2025504500A (ja) 抗ａｌｋ１抗体およびその使用方法
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
TW202529805A (zh) 用於耗損肥胖細胞的組成物及方法
HK40112898A (zh) 抗alk1抗体及其使用方法
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
HK40057787A (en) Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160923

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200225

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210914

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220324

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210914

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220622